Pharmaceuticals company Zydus Lifesciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations at Rs 65,279 million, up 18% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 4,799 million (7.4% of revenues). EBITDA for the quarter was Rs 21,255 million, up 30% YoY. EBITDA margin for the quarter stood at 32.6%, which is an improvement of 310 bps on a YoY basis. Net Profit, adjusted for exceptional items, was Rs 13,905 million, up 18% YoY. Capex (organic) for the quarter was Rs 3,202 million. FY25 Financial Highlights: Revenue from operations at Rs 2,32,415 million, up 19% over last year. • Research & Development (R&D;) investments for the year stood at Rs 18,555 million (8.0% of revenues). EBITDA for the year was Rs 70,585 million, up 31% YoY. EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year. Net Profit, adjusted for exceptional items, was Rs 47,451 million, up 23% YoY. Capex (organic) for the full year was Rs 12,140 million. Net Debt to Equity ratio as on 31st March, 2025 was -0.20x while Net Debt to EBITDA stood at -0.69x at the end of March, 2025. Net Cash (negative Net Debt) as on March 31st, 2025 was Rs 48,836 million. Sharvil Patel, Managing Director - Zydus Lifesciences said, "We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering.” Result PDF
Pharmaceuticals company Zydus Lifesciences announced Q3FY25 results Revenue from operations at Rs 52,691 million, up 17% over Q3FY24. Research & Development (R&D;) investments for Q3FY25 stood at Rs 5,031 million (9.5% of revenues). EBITDA for Q3FY25 was Rs 13,876 million, up 26% YoY. EBITDA margin for Q3FY25 stood at 26.3%, which is an improvement of 180 bps on a YoY basis. Net Profit for Q3FY25 was Rs 10,235 million, up 30% YoY. Capex (organic) for Q3FY25 was Rs 2,907 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said: We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations. Result PDF
Pharmaceuticals company Zydus Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations at Rs 52,370 million, up 20% over Q2FY24. Research & Development (R&D;) investments for the Q2FY25 stood at Rs 4,800 million (9.2% of revenues). EBITDA for the quarter was Rs 14,614 million, up 28% YoY. EBITDA margin for the quarter stood at 27.9% which is an improvement of 170 bps on a YoY basis. Net Profit for the Q2FY25 was Rs 9,112 million, up 14% YoY. Capex (organic) for the quarter was Rs 3,017 million. H1FY25 Financial Highlights: Revenue from operations at Rs 114,445 million, up 20% over H1FY24. Research & Development (R&D;) investments stood at Rs 8,725 million (7.6% of revenues). EBITDA was Rs 35,454 million, up 34% YoY. EBITDA margin stood at 31%, which is an improvement of 310 bps over H1FY24. Net Profit was Rs 23,311 million, up 24% YoY. Capex (organic) for the half year was Rs 6,031 million. Net Debt to Equity ratio as on 30th September, 2024 was -0.12x while Net Debt to EBITDA stood at -0.41x at the end of H1FY25. Net Cash (negative Net Debt) as on H1FY25 was Rs 25,906 million. Sharvil Patel, Managing Director - Zydus Lifesciences, said: Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core. Result PDF